2001
The term click chemistry is coined by Kolb, Finn and Sharpless: a highly selective set of chemical reactions that can occur even in a glass of water.
Read More
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies.
The term click chemistry is coined by Kolb, Finn and Sharpless: a highly selective set of chemical reactions that can occur even in a glass of water.
Read MorePrescher, Dube, and Bertozzi report the use of click chemistry to modify cells in living animals.
Read MoreBlackman, Royzen, and Fox pioneer the tetrazine ligation, an exceptionally powerful and efficient type of click chemistry.
Read MoreShasqi’s founder presents the foundational concepts of the Click Activated Protodrugs Against Cancer (CAPAC) Platform and shows the concept works in mice using the tetrazine ligation.
Read MoreShasqi shows that a cancer drug improved with the CAPAC Platform can lead to fewer side effects and better efficacy against tumors in mice.
Read MoreFDA and Australian Ethics Committee provide permission to proceed with first in human clinical study.
Read MoreShasqi presents anti-tumor responses for SQ3370, CAPAC’s lead candidate, in preclinical cancer model. (AACR)
Read MoreThe first patient dosed with Shasqi's SQ3370. First ever use of click chemistry in humans.
Read More